Comparative Pharmacology
Head-to-head clinical analysis: NORGESIC FORTE versus PARAFON FORTE DSC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORGESIC FORTE versus PARAFON FORTE DSC.
NORGESIC FORTE vs PARAFON FORTE DSC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norgesic Forte is a combination of orphenadrine citrate and aspirin (acetylsalicylic acid). Orphenadrine is a centrally acting muscle relaxant with anticholinergic and antihistaminic properties; it acts via blockade of nicotinic acetylcholine receptors at the neuromuscular junction and centrally as a non-competitive antagonist at NMDA receptors, reducing hypertonicity and spasm. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis.
Chlorzoxazone acts on the central nervous system (CNS) at the spinal cord level, possibly by depressing polysynaptic reflexes, producing skeletal muscle relaxation without affecting neuromuscular transmission.
1 tablet orally 3 times daily. Each tablet contains orphenadrine citrate 100 mg and paracetamol 500 mg.
Adults: 4 g (500 mg x 8 tablets) orally every 6-8 hours as needed; maximum 8 g (16 tablets) per 24 hours.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours; in elderly or hepatic impairment, half-life may be prolonged up to 12 hours, necessitating dose adjustment.
1-3 hours (terminal); clinically relevant for dosing intervals of 4-6 hours.
Renal (70% as unchanged drug and conjugates), fecal (20%), biliary (10%)
Primarily renal (85-95% as glucuronide conjugates and unchanged drug; <5% fecal).
Category C
Category C
Muscle Relaxant
Muscle Relaxant/Analgesic Combination